ALX ONCOLOGY HOLDINGS INC

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$17,567	$22,406
Short-term investments	110,190	160,330
Prepaid expenses and other current assets	6,595	5,923
Total current assets	134,352	188,659
Property and equipment, net	2,905	3,589
Long-term investments	3,524	35,411
Other assets	6,994	14,894
Total assets	$147,775	$242,553
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$4,497	$8,591
Payable and accrued liabilities due to related party	149	543
Term loan, current	435	—
Accrued expenses and other current liabilities	13,419	26,867
Total current liabilities	18,500	36,001
Term loan, non-current	9,469	9,639
Other non-current liabilities	6,188	7,201
Total liabilities	34,157	52,841
Commitments and contingencies (Note 12)
Stockholders’ equity
Common stock, $0.001 par value; 1,000,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 53,052,912 and 49,951,989 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	53	50
Additional paid-in capital	734,412	675,678
Accumulated other comprehensive income	275	256
Accumulated deficit	(621,122)	(486,272)
Total stockholders’ equity	113,618	189,712
Total liabilities and stockholders’ equity	$147,775	$242,553

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.